Beam Therapeutics Inc.
BEAM
$23.91
$0.944.09%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Net Income | -178.71% | -187.48% | -184.28% | 54.22% | 56.29% |
Total Depreciation and Amortization | 1.99% | 5.90% | 9.56% | 17.48% | 27.70% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 1.15% | 32.32% | 47.66% | 189.63% | 70.31% |
Change in Net Operating Assets | 40.55% | 10.81% | 5.35% | -26.95% | -33.71% |
Cash from Operations | -150.84% | -152.56% | -132.75% | 61.58% | 59.35% |
Capital Expenditure | 32.56% | 68.25% | 73.48% | 75.09% | 62.28% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -197.05% | 432.78% | 83.72% | 32.49% | 33.20% |
Cash from Investing | -218.56% | 1,702.57% | 157.53% | 79.89% | 99.06% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | 84.73% | 83.13% | 78.46% | 49.46% | 44.91% |
Issuance of Common Stock | 537.32% | 161.03% | -97.06% | -85.91% | -68.95% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | 100.00% | -17.79% |
Cash from Financing | 551.79% | 164.31% | -97.20% | -86.17% | -69.31% |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -117.52% | 591.73% | -177.60% | 597.01% | 254.94% |